Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 1/20 | 0.32 |
| ▸ | HTR7 | P34969 | 3/20 | 0.31 |
| ▸ | HTR1A | P08908 | 2/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6676385 | 0.84 | PNMT (0.35) | PNMTHTR7HTR1AACHE | |
| Hydrochloric Acid SCHEMBL3738279 | 0.83 | PNMT (0.33) | PNMTHTR7HTR1ACYP1A2CYP2A6 | |
| SCHEMBL3745212 | 0.82 | PNMT (0.43) | PNMTALDH1A1TSHRATMNPSR1 | |
| SCHEMBL3750229 | 0.79 | PNMT (0.36) | PNMTHTR7HTR1AACHECYP1A2 | |
| SCHEMBL3262857 | 0.77 | CYP1A2 (0.33) | CYP1A2CYP2A6ALDH1A1 | |
| SCHEMBL3675927 | 0.77 | MEN1 (0.38) | PNMTHTR7HTR1AACHECYP1A2 | |
| SCHEMBL3680491 | 0.76 | NPC1 (0.36) | PNMTHTR7HTR1AALDH1A1TSHR | |
| Hydrochloric Acid SCHEMBL3750227 | 0.72 | PNMT (0.35) | PNMTHTR7HTR1AACHECYP1A2 | |
| SCHEMBL3742379 | 0.71 | PNMT (0.37) | PNMTHTR7HTR1AACHECYP1A2 | |
| SCHEMBL3672084 | 0.71 | PNMT (0.43) | PNMTHTR7HTR1AACHECYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7732643-B2 | Transition metal complex, catalyst for olefin polymerization, and process for producing olefin polymer with the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-06-08 | — | — | US | disclosed |
| US-20100048933-A1 | TRANSITION METAL COMPLEX, CATALYST FOR OLEFIN POLYMERIZATION, AND PROCESS FOR PRODUCING OLEFIN POLYMER WITH THE SAME | HANAOKA HIDENORI | 2010-02-25 | — | — | US | disclosed |
| US-20090054607-A1 | Transition metal complex, catalyst for olefin polymerization, and process for producing olefin polymer with the same | HANAOKA HIDENORI | 2009-02-26 | — | — | US | disclosed |
| US-20040242410-A1 | Transition metal complex, catalyst for olefin polymerization, and process for producing olefin polymer with the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2004-12-02 | — | — | US | disclosed |
| EP-1426379-A1 | TRANSITION METAL COMPLEX,CATALYST FOR OLEFIN POLYMERIZATION, AND PROCESS FOR PRODUCING OLEFIN POLYMER WITH THE SAME | Sumitomo Chemical Company, Limited (JP) | 2004-06-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054607-A1 | Transition metal complex, catalyst for olefin polymerization, and process for producing olefin polymer with the same | C1R, C1S, AP1M1 | PNMT 1804/4885HTR7 3440/4885HTR1A 1017/4885 |
| US-20100048933-A1 | TRANSITION METAL COMPLEX, CATALYST FOR OLEFIN POLYMERIZATION, AND PROCESS FOR PRODUCING OLEFIN POLYMER WITH THE SAME | C1R, C1S, AP1M1 | PNMT 1804/4885HTR7 3440/4885HTR1A 1017/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.